Skip to main content
Midas Edge

ArriVent BioPharma Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Series A · ​ · Series B · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​
​ · ​ · convertible preferred stock · ​ · convertible preferred stock · ​ · ​ · Common stock · ​ · Subscriptions · ​ · paid-in · ​ · Accumulated · ​ · ​
​ · ​ · Shares · Amount · Shares · Amount · Shares · Amount · ​ · receivable · capital · deficit · Total
Balance January 1, 2024150,000,000​$149,865147,619,034​$154,625​​2,745,480​$—​$—​$4,652​$(157,845)​$(153,193)
Issuance of common stock in initial public offering, net of issuance costs of $18,032—​——​—​11,180,555​1​​—​183,216​—​183,217
Conversion of convertible preferred stock into common stock​(150,000,000)​​(149,865)​(147,619,034)​​(154,625)​​19,567,306​​2​​—​​304,488​​—​304,490
Exercise of stock options—​——​—​409​—​​—​1​—​1
Stock-based compensation expense—​——​—​—​—​​—​625​—​625
Net loss—​——​—​—​—​​—​—​(17,417)​(17,417)
Balance, March 31, 2024—​​——​​—​33,493,750​​3​​—​​492,982​​(175,262)​​317,723
Exercise of stock options—​——​—​15,340​—​​—​44​—​44
Stock-based compensation expense—​——​—​—​—​​—​766​—​766
Net loss—​——​—​—​—​​—​—​(21,874)​(21,874)
Balance, June 30, 2024—​​——​​—​33,509,090​​3​​—​​493,792​​(197,136)​​296,659
Exercise of stock options—​——​—​185,265​—​​—​532​—​532
Stock-based compensation expense—​——​—​—​—​​—​866​—​866
Net loss—​——​—​—​—​​—​—​(20,564)​(20,564)
Balance, September 30, 2024—​$——​$—​33,694,355​$3​$—​$495,190​$(217,700)​$277,493

STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Series A · ​ · Series B · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​
​ · ​ · convertible preferred stock · ​ · convertible preferred stock · ​ · ​ · Common stock · ​ · Subscriptions · ​ · paid-in · ​ · Accumulated · ​ · ​
​ · Shares · Amount · Shares · Amount · Shares · Amount · ​ · receivable · capital · deficit · Total
Balance January 1, 2023150,000,000​$149,865104,761,894​$109,706​2,597,738​$—​$—​$3,403​$(88,512)​$(85,109)
Issuance of Series B convertible preferred stock at $1.05 per share, net of issuance costs of $57—​—42,857,140​44,943​—​—​​—​—​—​—
Exercise of stock options—​——​—​11,417​—​​—​26​—​26
Stock-based compensation expense—​——​—​—​—​​—​166​—​166
Net loss—​——​—​—​—​​—​—​(12,172)​(12,172)
Balance, March 31, 2023150,000,000​​149,865147,619,034​​154,649​2,609,155​​—​​—​​3,595​​(100,684)​​(97,089)
Issuance costs of Series B convertible preferred stock​—​​—​—​​(24)​​—​​—​​—​​—​​—​​—
Repurchase of common stock​—​​—​—​​—​​(7,387)​​—​​—​​—​​—​​—
Exercise of stock options—​——​—​1,647​—​​—​4​—​4
Stock-based compensation expense—​——​—​—​—​​—​193​—​193
Net loss—​——​—​—​—​​—​—​(21,567)​(21,567)
Balance, June 30, 2023150,000,000​​149,865147,619,034​​154,625​2,603,415​​—​​—​​3,792​​(122,251)​​(118,459)
Exercise of stock options—​——​—​63,714​—​​(106)​145​—​39
Stock-based compensation expense—​——​—​—​—​​—​217​—​217
Net loss—​——​—​—​—​​—​—​(14,401)​(14,401)
Balance, September 30, 2023150,000,000​$149,865147,619,034​$154,625​2,667,129​$—​$(106)​$4,154​$(136,652)​$(132,604)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.